Australia markets closed

Oculis Holding AG (CR5.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
10.20-0.10 (-0.97%)
At close: 08:14PM CEST
Full screen
Previous close10.30
Open10.10
Bid10.20 x N/A
Ask10.50 x N/A
Day's range10.20 - 10.30
52-week range8.45 - 13.00
Volume0
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Oculis and EURETINA Announces the Ramin Tadayoni Award

    ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. In memory of the Company’s Chief Scientific Officer and a world-renowned retina specialist, EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has

  • GlobeNewswire

    Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

    Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trialRapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43Licaminlimab was well tolerated similar to vehicle Company plans to finalize Phase 3 devel

  • GlobeNewswire

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: O